Glioblastoma tumor-associated antigens (GBM TAAs)

Glioblastoma tumor-associated antigens (TAAs) are a heterogeneous group of proteins that are preferentially expressed by glioblastoma cells, making them ideal targets for precision immunotherapy (Source: NIH, National Cancer Institute). These antigens include neoantigens like the EGFRvIII mutation, which is entirely tumor-specific, and overexpressed proteins such as IL13Ra2, HER2, and Survivin (Source: PubMed, PMID: 30232639). They play critical roles in tumor survival, proliferation, and resistance to apoptosis, contributing to the aggressive nature of glioblastoma multiforme (Source: PubMed, PMID: 28811431). Therapeutic approaches targeting these antigens include peptide vaccines like Rindopepimut and SurVaxM, as well as advanced CAR T-cell therapies designed to recognize surface-bound TAAs (Source: ClinicalTrials.gov). Despite their potential, the high degree of intratumoral heterogeneity in glioblastoma often leads to antigen escape, where the tumor evolves to lose the targeted antigen, necessitating the development of multi-valent targeting strategies (Source: PubMed, PMID: 31160680). The blood-brain barrier and the immunosuppressive microenvironment of the central nervous system remain significant challenges for drugs interacting with these antigens (Source: PubMed, PMID: 32433519).

Other names

Glioma-associated antigensGBM antigensBrain tumor antigensGlioblastoma-specific antigens

Immunotherapeutic targeting of tumor-specific or overexpressed proteins to induce T-cell mediated cytotoxicity or antibody-dependent cellular cytotoxicity against glioblastoma cells.